<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366884</url>
  </required_header>
  <id_info>
    <org_study_id>ACI/2015</org_study_id>
    <nct_id>NCT02366884</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis (Atavistic Chemotherapy).</brief_title>
  <official_title>Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Frank Arguello Cancer Clinic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Frank Arguello Cancer Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cell behavior that the investigators regard as &quot;malignant,&quot; including: cell autonomy;
      invasion and digestion of surrounding normal tissues; migration and colonization of distant
      organs; ability to develop resistance to drugs, temperature, or radiation; and ability to
      kill the host, are not only characteristics of cancer cells, but of pathogenic and/or
      opportunistic unicellular organisms (bacteria, fungi and protozoa). Rudolf Virchow
      (1821-1902), the father of modern pathology, first pointed out the resemblance between the
      biological behavior of cancer cells and that of single-celled organisms when causing
      infections. He thought, incorrectly, that cancer cells were cells infected with bacteria and
      had acquired their pathogenic behavior from them. Others later postulated that the behavior
      of cancer cells was likely due to the re-expression of past traits and behaviors (atavism)
      derived from their past evolutionary experience as independent, single-celled organisms from
      which all cells in multicellular organisms originated. In other words, the behavior of
      pathogenic unicellular organisms, including: unlimited replicative potential; capacity for
      invasion, migration, and metastases; abilities to evade the host's immune system, to generate
      multi-drug resistance; and to kill a host, are what the investigators define as &quot;cancer&quot; when
      one of the investigators cells re-express these past ancestral traits. This reversion or
      de-evolution of a differentiated cell to its ancestral undifferentiated, unicellular form has
      been named &quot;Atavistic Metamorphosis.&quot;

      This does not imply that cancer cells are bacteria, protozoa, or yeasts. It means that cancer
      cells express functions and/or behaviors similar to their ancestral parents, the unicellular
      organisms from which our cells originated.

      If this is true, a combination of drugs that are effective to eradicate certain unicellular
      organisms may work in cancer treatment.

      The principal objective of this study is to determine whether there is a benefit for patients
      with advanced, metastatic and terminal cancers to be treated with combinations of selected
      drugs conventionally used in medical practice to kill bacterial, fungal and protozoal cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, randomized, single-blind, response-adaptive trial
      conducted at two sites in patients who have tried conventional therapy and failed or have
      refused conventional therapy. This study is being conducted to determine the efficacy of
      combinations of marketed drugs against unicellular organisms in cancer treatment. The
      products under investigation include FDA- and SSA-approved anti-bacterial, anti-fungal and
      anti-protozoan drugs with documented anti-cancer properties. The drugs under study are
      compatible with each other, and used at pharmacological dosages known to be tolerable and
      safe in humans and/or cancer patients with limited adverse effects. Patients receive
      treatment for 10 to 12 months. The duration of treatment is depended on the drugs
      investigated. It is hypothesized that regression will occur within 6 months and treatment
      will be continued with the assumption that this may prevent recurrences. Outcomes will be
      measured objectively and assessments appropriate for the type of cancer treated. Outcome
      measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using
      weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung
      tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal
      tumors (e.g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET
      scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15.3, CA-19-9,
      etc. and other laboratory studies to monitor response. The overall goal of this study is to
      understand the efficacy of atavistic chemotherapy that may mediate metastatic or terminal
      cancer regression or cure.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response</measure>
    <time_frame>6 Months</time_frame>
    <description>Tumor regression will be measrued objectively and assessments appropriate for the type of cancer treated. Outcome measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal tumors (e.g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15.3, CA-19-9 and other laboratory studies to monitor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response</measure>
    <time_frame>12 Months</time_frame>
    <description>Tumor regression will be measrued objectively and assessments appropriate for the type of cancer treated. Outcome measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal tumors (e.g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15.3, CA-19-9 and other laboratory studies to monitor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety as measured by the incidence of adverse events in each intervention group</measure>
    <time_frame>12 Months</time_frame>
    <description>Determine the percentage of incidence of adverse events in each intervention group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Anti-bacterial agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of two selected anti-bacterial agents with documented anti-cancer properties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-fungal agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of two selected anti-fungal agents with documented anti-cancer properties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-protozoal agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of two selected anti-protozoal agents with documented anti-cancer properties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-bacterial + anti-fungal + anti-protozoal agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Bacterial Agents</intervention_name>
    <description>Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine</description>
    <arm_group_label>Anti-bacterial agents</arm_group_label>
    <arm_group_label>Anti-bacterial + anti-fungal + anti-protozoal agents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Fungal Agents</intervention_name>
    <description>Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole</description>
    <arm_group_label>Anti-fungal agents</arm_group_label>
    <arm_group_label>Anti-bacterial + anti-fungal + anti-protozoal agents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Protozoal Agents</intervention_name>
    <description>Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole</description>
    <arm_group_label>Anti-protozoal agents</arm_group_label>
    <arm_group_label>Anti-bacterial + anti-fungal + anti-protozoal agents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with malignant disease confirmed histologically that is considered
             untreatable, progressive and fatal within the next 16 months.

          -  Patient with an expectation of life greater than 3 months.

          -  Patients with malignant disease that may be evaluated or measured clinically either
             through radiographic studies, visually, histologically, in serum or blood tumor
             markers, or through any other method medical approved for that disease.

        Exclusion Criteria:

          -  Patients over 75 years of age.

          -  Patients who are pregnant.

          -  Patients that have a known allergy to any of the drugs planned for use.

          -  Patients with renal, hepatic, pulmonary, cardiovascular compromise, or other systemic
             or other clinical conditions such as AIDS, tuberculosis, etc., which, in the opinion
             of the Investigator, may pose a risk to the subject.

          -  Malignancies of hemato-lymphatic origin (leukemias and lymphomas)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Arguello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Frank Arguello Cancer Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Arg√ºello-Astorga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Ciencia y Medicina Genomica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atavistic Chemotherapy Clinical Trial</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Frank Arguello Cancer Clinic</name>
      <address>
        <city>San Jose del Cabo</city>
        <state>Baja California Sur</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ciencia y Medicina Genomica</name>
      <address>
        <city>Torreon</city>
        <state>Coahuila</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://atavisticchemotherapy.com/wp-content/uploads/2017/11/ENGLISHMELANOMA_CASES.pdf</url>
    <description>STAGE IV MELANOMA PATIENTS TREATED WITH ATAVISTIC CHEMOTHERAPY</description>
  </link>
  <link>
    <url>http://atavisticchemotherapy.com/wp-content/uploads/2017/11/ENGLISHBREASTCANCER_CASES.pdf</url>
    <description>STAGE IV BREAST CANCER PATIENTS TREATED WITH ATAVISTIC CHEMOTHERAPY</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=KwX43KPbpDY</url>
    <description>What is Atavistic Chemotherapy?</description>
  </link>
  <link>
    <url>http://www.atavisticchemotherapy.com</url>
    <description>Website Atavistic Chemotherapy</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=nvJFI3ChOUU</url>
    <description>Facts of Evolution</description>
  </link>
  <reference>
    <citation>Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988 Dec 1;48(23):6876-81.</citation>
    <PMID>3180096</PMID>
  </reference>
  <reference>
    <citation>Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood. 1998 Apr 1;91(7):2482-90.</citation>
    <PMID>9516149</PMID>
  </reference>
  <reference>
    <citation>Arguello F, Baggs RB, Duerst RE, Johnstone L, McQueen K, Frantz CN. Pathogenesis of vertebral metastasis and epidural spinal cord compression. Cancer. 1990 Jan 1;65(1):98-106.</citation>
    <PMID>2293874</PMID>
  </reference>
  <reference>
    <citation>Arguello F, Furlanetto RW, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/Sld and W/Wv). Cancer Res. 1992 Apr 15;52(8):2304-9.</citation>
    <PMID>1559233</PMID>
  </reference>
  <reference>
    <citation>Arguello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Effect of IL-1 on experimental bone/bone-marrow metastases. Int J Cancer. 1992 Nov 11;52(5):802-7.</citation>
    <PMID>1428234</PMID>
  </reference>
  <reference>
    <citation>Arguello F, Sterry JA, Zhao YZ, Alexander MR, Shoemaker RH, Cohen HJ. Two serologic markers to monitor the engraftment, growth, and treatment response of human leukemias in severe combined immunodeficient mice. Blood. 1996 May 15;87(10):4325-32.</citation>
    <PMID>8639792</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Frank Arguello Cancer Clinic</investigator_affiliation>
    <investigator_full_name>Frank Arguello, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>malignant</keyword>
  <keyword>atavistic chemotherapy</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Antiprotozoal Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

